Neihulizumab granted fast track designation by the FDA for steroid refractory acute graft versus host disease (SR-aGVHD)

FDA grants this immune checkpoint regulator targeting PSGL-1 fast track designation following demonstrated clinical proof of concept and safety in more than 170 patients. It is currently being studied in a Phase 1b multi-dose trial in SR-aGVHD.

Source:

Biospace Inc.